article · Iraq Medical Journal
Description of the article 
 The need for more precise serodiagnosis marker for hepatocellular carcinoma (HCC) is always a must for many reasons:
 
 Serodiagnosis is generally non-invasive and safe technique to have a human sample.
 Different radiological modalities, although its accuracy is progressing, but many times its result is misinterpreted.
 The current extensively used seromarker, alpha fetoprotein (AFP), doesn’t exceed 70% for sensitivity and 90% for specificity.
 Many of clinicians requesting AFP tests, whether in HCC management or related diseases, as, hepatitis C or B infections don’t know exactly the diagnostic accuracy levels of AFP.
 The need for spectrophotometric marker, rather than molecular or radio or Elisa parameter as a cost effective goal.
 The earlier the detection of HCC, the longer the patient life.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.22317/imj.v6i4.1206
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
